---
title: Exagamglogene Autotemcel for Severe Sickle Cell Disease
date: '2024-04-25'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38661449/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20240425181109&v=2.18.0.post9+e462414
source: N Engl J Med
description: 'CONCLUSIONS: Treatment with exa-cel eliminated vaso-occlusive crises
  in 97% of patients with sickle cell disease for a period of 12 months or more. (CLIMB
  SCD-121; ClinicalTrials.gov number, ...'
disable_comments: true
---
CONCLUSIONS: Treatment with exa-cel eliminated vaso-occlusive crises in 97% of patients with sickle cell disease for a period of 12 months or more. (CLIMB SCD-121; ClinicalTrials.gov number, ...